Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 862 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... April 15, 2022 Cancer target missed for 55,000 patients over 6 years September 22, 2021 Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t... October 15, 2021 FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection... April 25, 2023 Load more HOT NEWS First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years... Scanxiety Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2...
